Insider Buying: Ondine Biomedical Inc. (LON:OBI) Insider Purchases 149,225 Shares of Stock

Ondine Biomedical Inc. (LON:OBI) insider Carolyn Cross purchased 149,225 shares of the firm’s stock in a transaction on Monday, February 3rd. The stock was bought at an average price of GBX 13 ($0.16) per share, with a total value of £19,399.25 ($24,134.42).

Carolyn Cross also recently made the following trade(s):

• On Thursday, January 30th, Carolyn Cross bought 200,775 shares of Ondine Biomedical stock. The shares were purchased at an average cost of GBX 12 ($0.15) per share, for a total transaction of £24,093 ($29,973.87).

Ondine Biomedical Price Performance

OBI opened at GBX 12.55 ($0.16) on Tuesday. Ondine Biomedical Inc. has a twelve month low of GBX 4.50 ($0.06) and a twelve month high of GBX 13.30 ($0.17). The company has a current ratio of 0.80, a quick ratio of 8.26 and a debt-to-equity ratio of 1,847.37. The firm has a market cap of £34.80 million, a price-to-earnings ratio of -418.33 and a beta of 0.10. The company has a fifty day simple moving average of GBX 9.25 and a 200 day simple moving average of GBX 8.01.

About Ondine Biomedical

Ondine Biomedical is a life sciences company leading the charge in breakthrough photodisinfection-based therapies to prevent and treat serious infections, including those caused by existing, emerging, and antimicrobial-resistant pathogens.

Our vision is a world free from infections. We have created a patented, platform technology (photodisinfection) to provide simple solutions to complex infections across different therapeutic areas in healthcare and industry settings.